Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsGetting an anti-VEGF injection within 35 days before cataract surgery could significantly lower the risk of postoperative macular edema in patients with retinal vein occlusion (RVO). A retrospective study found that eyes treated recently had a 12.5% edema rate vs. 57.1% in those treated more than 35 days out. Researchers suggest pretreatment may be beneficial for all RVO patients, regardless of prior disease activity.
Cataract surgery is a known visual game-changer for patients with retinal vein occlusion (RVO) — but it comes with a catch. The procedure significantly raises the risk of postoperative macular edema (PME), a complication that can undermine the very vision gains surgery is meant to deliver. New research published in BMC Ophthalmology suggests that timing an anti-VEGF injection close to surgery could be the key to keeping that risk in check.
Researchers at Stony Brook University Hospital retrospectively reviewed 53 eyes from 51 RVO patients who underwent cataract surgery. They found that eyes receiving anti-VEGF therapy within 35 days before surgery had dramatically lower PME rates compared to those treated earlier or not at all — pointing to a narrow but meaningful protective window.
By the Numbers:
Why it matters: For clinicians managing RVO patients heading into cataract surgery, this study offers a practical, actionable insight: a well-timed anti-VEGF injection could meaningfully reduce a common and vision-threatening complication. Experts recommend baseline macular OCT and shared decision-making with the surgical team for all RVO patients pre-op.
